{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-24-000039","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.805792+00:00","generated_at":"2026-05-31T13:01:39.808517+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AnaptysBio Q2 net loss $46.7M; cash $393.5M; ANB032 Phase 2b enrollment complete, data Dec 2024","bullets":["Net loss of $46.7M ($1.71 per share) for Q2 2024, vs $39.8M loss ($1.50) in Q2 2023.","Cash & investments $393.5M as of June 30, 2024; runway reiterated through year-end 2026.","Completed enrollment (~200 patients) for ANB032 Phase 2b in atopic dermatitis; top-line data expected Dec 2024.","Rosnilimab Phase 2b RA top-line data accelerated to Q1 2025; Phase 2 UC data now expected Q1 2026.","IND for ANB033 (anti-CD122) accepted by FDA; Phase 1 trial initiation anticipated in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-24-000039","json":"https://secwatch.observer/filing/0001370053-24-000039.json","markdown":"https://secwatch.observer/filing/0001370053-24-000039.md","text":"https://secwatch.observer/filing/0001370053-24-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000039/0001370053-24-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000039/anab-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:01:39.808517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}